Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Systemic therapies for advanced HCC

Arndt Vogel • 9 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Ramucirumab Regorafenib Sorafenib

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, explores future therapies and systemic treatments for advanced hepatocellular carcinoma (HCC), including combination therapies and approaches involving immuno-oncology. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.

More from Arndt Vogel

2:17
The role of the PLATON Network in enhancing precision oncology
Arndt Vogel • 3 Jul 2023
3:14
RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC
Arndt Vogel • 3 Jul 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
0:39
Analysis of the European/North American subgroup in the RATIONALE-301 trial
Arndt Vogel • 3 Jul 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals